Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy

Cancer Immunology, Immunotherapy

Volumn 56, Issue 5, 2007, Pages 731-737

  Hombach, Andreas ^a   Abken, Hinrich ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

4 1BB; Adoptive immunotherapy; CD28; Costimulation; Immunoreceptor; OX40; Recombinant TCR

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BIOENGINEERING; CELL SURVIVAL; CONFERENCE PAPER; CYTOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR IMMUNITY;

EID: 33847367680     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0249-0     Document Type: Conference Paper

References (34)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
2. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685
3. Schumacher TN (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2:512-519
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Opalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A., de Vries CR, Rogers-Freezer LJ, Maroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129
5. Gross G, Gorochov G, Waks T, Eshhar Z (1989) Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21:127-130
6. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-724
7. Abken H, Hombach A, Heuser C (2003) Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 9:1992-2001
8. Hombach A, Heuser C, Abken H (2002) The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther 2:211-226
9. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Kruis W, Pohl C, Abken H (1997) T cell targeting of TAG72 + tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 113:1163-1170
10. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Honemann D, Prince HM, Darcy PK, Kershaw MH (2005) Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 102:19051-19056
11. Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B (1996) Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 2:1001-1008
12. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJDarcy PK (2002) Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 169:5780-5786
13. Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IG, Abken H (2006) A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3ζ-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55:1156-1164
14. Hombach A, Muche JM, Gerken M, Gellrich S, Heuser C, Pohl C, Sterry W, Abken H (2001) T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells. Gene Ther 8:891-895
15. Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C, Abken H (2001) CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J Immunol 167:1090-1096
16. Hombach A, Köhler H, Rappl G, Abken H (2006) Human CD4+ T cells lyse tumor cells via granzyme/perforin upon circumvention of MHC restriction by grafting with a recombinant, antibody-derived immunoreceptor. J Immunol 177:5668-5675
17. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105:3087-3093
18. Brocker T, Riedinger M, Karjalainen K (1996) Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur J Immunol 26:1770-1774
19. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H (2001) T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 61:1976-1982
20. Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL (1998) Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 77:181-187
21. Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26:2304-2309
22. Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791-2797
23. Eshhar Z, Waks T, Bendavid A, Schindler DG (2001) Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248:67-76
24. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20:70-75
25. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155-3163
26. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H (2001) Tumor specific T cell activation by recombinant immunoreceptors: CD3zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol 167:6123-6131
27. Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 11:371-379
28. Geiger TL, Nguyen P, Leitenberg D, Flavell RA (2001) Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in lymphocytes. Blood 98:2364-2371
29. Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172:104-113
30. Zhong XS, Matsushita M, Saudemont A, Santos E, Sadelain M (2006) Integrated CD28 and 4-1BB signals strongly potentiate CD8+ T cell mediated eradication of metastatic prostate cancer. Mol Ther 13(Suppl1):S103
31. Weinberg AD (2002) OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23:102-109
32. Huard B, Schneider P, Mauri D, Tschopp J, French LE (2001) T cell costimulation by the TNF ligand BAFF. J Immunol 167:6225-6231
33. Mestas J, Hughes CC (2001) Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation. J Immunol 167:4378-4385
34. Lamers CH, Sleijfer S., Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20-e22